Brief: GRI Bio Completes Enrollment In Phase 2A Study Of GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis (“IPF”)
01/07/2025 13:54
July 1 (Reuters) - GRI Bio Inc GRI.O: GRI BIO COMPLETES ENROLLMENT IN PHASE 2A STUDY OF GRI-0621 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (“IPF”) GRI BIO INC - TOPLINE RESULTS FROM PHASE 2A STUDY EXPECTED IN Q3 2025 GRI BIO INC - GRI-0621 DEMONSTRATED SAFE AND WELL-TOLERATED IN INTERIM SAFETY RESULTS Source text: ID:nGNXg0PQz Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027